On February 25,  medical device company Stryker announced the complete acquisition of Arrinex Inc. Arrinex is an ear, nose, and throat (ENT) product-based medical device company in California. The company developed ClariFix, a technology that treats chronic rhinitis. This cryoablation-based technology targets 24 million patients in the US each year. Arrinex was founded in 2013 and backed by 7 Gate Ventures, and now is set to become a part of Stryker’s ENT product portfolio.

The question is, who are the winners and losers in this deal? The financial arrangement is undisclosed, but this common theme for market-leading giants of healthcare, growing through acquisition, has been well-replicated in the past. From the likes of Johnson & Johnson, Abbott, and Stryker, market leaders have valued acquisition for product expansion much greater than in-house development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Historically, this business methodology has been discouraged, since it over-values unjustified inventions, minimises innovation by depleting small market players, and shows minimal cost-benefit due to high investment costs. However, this is beginning to change.

Acquisition seems to be the smarter and more efficient way for a large medical device organisation to function. With rising device regulations, import regulations, expansion of international investment opportunities, and rising costs of R&D, acquisition for business expansion just makes sense.

By eliminating R&D losses, acquiring solidified leads and accounts, minimising regulatory costs through already justified products, and obtaining international presence through acquisition, the traditional R&D-based business models seem unreasonable in 2019.

So in a deal like the one with Arrinex, Stryker truly benefits from the transaction, as of course does 7 Gate Ventures. The concern is Arrinex. Will it be able to manage its product and continue to grow within the organisation? Will it be able to meet the client demands that Stryker is set to offer? These are the sort of questions that new innovators should be asking and learning from.